Financial Performance - Total operating revenue for the first half of 2018 reached ¥341,423,225.17, representing a 98.10% increase compared to ¥172,348,187.65 in the same period last year[17]. - Net profit attributable to shareholders was ¥40,709,165.23, up 38.61% from ¥29,370,624.56 in the previous year[17]. - Net profit after deducting non-recurring gains and losses was ¥39,516,708.84, reflecting a 39.19% increase from ¥28,389,530.66[17]. - Basic earnings per share were ¥0.3392, a 32.81% increase compared to ¥0.2554 in the same period last year[17]. - The company achieved operating revenue of 341 million CNY and a net profit attributable to shareholders of 40.71 million CNY, showing stable growth compared to the same period last year[24]. - The company reported a total of 1.19 billion CNY in non-recurring gains and losses, with government subsidies contributing 602.16 million CNY[21]. - The company reported a total profit for the first half of 2018 of CNY 47,370,359.16, compared to CNY 34,209,851.25 in the same period of 2017, an increase of approximately 38.5%[146]. - The company reported an investment income of ¥705,525.48, contributing 1.49% to the total profit[49]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥728,376,481.15, a 15.19% increase from ¥632,298,868.32 at the end of the previous year[17]. - Current liabilities rose to CNY 179,730,738.79, compared to CNY 105,004,687.62, marking an increase of about 70.9%[138]. - The total liabilities increased to CNY 189,340,738.79 from CNY 114,614,687.62, marking a growth of about 65.1%[138]. - The company's cash and cash equivalents decreased by 58.18% to ¥56,931,570.60 due to the previous year's IPO fundraising[45]. - The company's cash and cash equivalents increased to ¥131,514,586.72 from ¥74,582,545.57, representing an increase of approximately 76%[136]. Research and Development - The company increased its R&D investment to 25.35 million yuan, a significant increase of 68.56% compared to the previous year[37]. - The company has developed a new production process for Tigecycline, becoming one of the few domestic companies with stable production capabilities for Tigecycline raw materials and formulations[36]. - The company has completed the optimization of the production process for the raw material of Adefovir Dipivoxil and is conducting stability tests and clinical trials[37]. - The company has made adjustments to some R&D projects based on current research conditions[58]. Market and Sales - The main products include Torasemide injection, Lansoprazole injection, Tigecycline injection, and Cefoperazone sodium injection, with a total of 43 varieties and 65 drug production approval numbers[24]. - The sales revenue of injectable Torasemide reached 139.10 million yuan, a year-on-year increase of 158.64%, with a sales volume of 10.84 million units, up 55.50%[37]. - The sales revenue of injectable Lansoprazole was 36.39 million yuan, increasing by 67.75%, with a sales volume of 1.58 million units, up 23.82%[37]. - The sales revenue of injectable Cefotiam was 53.69 million yuan, a year-on-year increase of 152.86%, with a sales volume of 3.59 million units, up 18.59%[37]. Risks and Challenges - The company faces risks including drug quality, R&D project performance, and price reduction in drug bidding[5]. - The company faces risks related to drug quality, industry policy changes, and the potential for research and development projects to not meet expectations[70][71][72]. - The company is actively monitoring industry policy changes and adjusting strategies to mitigate risks associated with drug pricing and procurement policies[73]. Corporate Governance and Shareholder Matters - The company has established a sound governance structure and operational system to support its current scale and development needs[75]. - The company held three shareholder meetings during the reporting period, with participation rates of 66.91%, 62.92%, and 59.96% respectively[78]. - The first employee stock ownership plan was approved, with shares purchased and locked for 12 months, aiming to align employee interests with company performance[87]. - The company has not distributed cash dividends or bonus shares for the half-year period, focusing on reinvestment[79]. Environmental Compliance - The company is classified as a key pollutant discharge unit and has implemented a wastewater treatment system with a design capacity of 40 tons per hour, ensuring compliance with the wastewater discharge standards[101][102]. - The wastewater treatment process includes "anoxic tank + biological contact oxidation + sedimentation," and the treated water meets the GB8978-1996 Class III standard before being discharged[102]. - Zhenjiang Derui has not reported any instances of exceeding discharge limits in its wastewater, air, noise, or groundwater monitoring[104]. Financial Management - The company has engaged in entrusted financial management, with a total of 2,000 million yuan in bank financial products, all of which are from idle raised funds and self-owned funds[62]. - The company has a total of 1,000 million yuan in entrusted financial management from idle raised funds, with no overdue amounts[62]. - The company has not reported any changes in the use of raised funds during the reporting period[60]. Accounting Policies - The company has implemented accounting policies in accordance with the relevant financial regulations, ensuring accurate financial reporting[174]. - The financial statements prepared by the company comply with the requirements of the enterprise accounting standards, reflecting the company's financial position, operating results, and cash flows accurately[177]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired in a business combination[182].

南京海辰药业股份有限公司 2018 年第一季度报告全文 南京海辰药业股份有限公司 2018 年第一季度报告 2018-040 2018 年 04 月 1 南京海辰药业股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)李小卫声明：保证季度报告中财务报表的真实、准确、完整。 2 南京海辰药业股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 163,600,239.67 | 75,587,056.72 | 116.44% | | 归属于上市公司股东的净利润（元） | 16,986,702.43 ...

Financial Performance - The company's operating revenue for 2017 was ¥455,034,585.52, representing a 62.03% increase compared to ¥280,827,571.15 in 2016[18]. - The net profit attributable to shareholders for 2017 was ¥65,600,505.52, up 45.02% from ¥45,236,377.77 in 2016[18]. - The net profit after deducting non-recurring gains and losses was ¥61,336,941.73, a 36.50% increase from ¥44,935,304.66 in 2016[18]. - The basic earnings per share for 2017 was ¥0.8375, an increase of 11.09% from ¥0.7539 in 2016[18]. - The total assets at the end of 2017 were ¥632,298,868.32, a 70.53% increase from ¥370,776,229.63 at the end of 2016[18]. - The net assets attributable to shareholders at the end of 2017 were ¥517,684,180.70, an increase of 87.49% from ¥276,113,510.62 at the end of 2016[18]. - The net cash flow from operating activities for 2017 was ¥46,557,481.82, a 23.37% increase from ¥37,737,790.97 in 2016[18]. - The weighted average return on equity for 2017 was 13.72%, down from 17.77% in 2016, reflecting a decrease of 4.05%[18]. Revenue Breakdown - The company's total revenue for the year was 455 million yuan, with a net profit attributable to shareholders of 66 million yuan[26]. - The core product, injectable Torasemide, generated sales revenue of 140.34 million yuan, selling 14.7 million units, maintaining a leading market share[43]. - Antibiotics contributed ¥107,402,284.68, accounting for 23.60% of total revenue, with a year-on-year growth of 55.89%[53]. - The revenue from diuretics reached ¥140,340,881.39, making up 30.84% of total revenue, reflecting a 63.75% increase from the previous year[53]. - The revenue from immune regulation products increased by 73.00%, reaching ¥72,197,768.61, highlighting strong market demand[53]. Product Development and R&D - The company has 43 product varieties and 65 drug production approval numbers, with 37 products included in the 2017 National Medical Insurance Directory[26]. - The company has developed a lyophilized powder injection process for Torasemide, significantly improving its solubility and stability, leading to increased clinical safety and recognition in multiple treatment guidelines[31]. - R&D investment amounted to 35.46 million yuan, accounting for 7.79% of operating revenue, with a year-on-year increase of 50.09%[43]. - The company has entered the registration process for multiple new drugs, including hydrochloride landiolol and flupirtine maleate, which are expected to enhance product lines and market competitiveness[47]. - The company is preparing to initiate clinical trials for flupirtine maleate capsules, which is expected to further enrich its product offerings[47]. Market Strategy and Expansion - The company adopted a refined promotion model in response to the "two-invoice system" reform, which significantly increased sales revenue and market control[30]. - The company aims to enhance product profitability by focusing on high-margin products such as diuretics, digestive drugs, and high-end antibiotics[30]. - The company has established a marketing network covering over 1,000 distributors and approximately 3,000 hospitals nationwide, enhancing its market reach and academic collaboration[38]. - The company plans to expand its R&D team and advance over ten new products in accordance with the consistency evaluation requirements for generic drugs[88]. - The company plans to enter two new international markets in the upcoming year, aiming for a 10% contribution to overall revenue[190]. Risk Management - The company has identified several risks, including R&D project underperformance and price reduction risks in drug bidding[5]. - The company faces risks related to R&D project failures and will optimize its R&D strategy to mitigate these risks by focusing on key projects and exploring new research avenues[93]. - The company is exposed to pricing risks in drug tenders due to national healthcare reforms and will develop targeted strategies to maintain product competitiveness[94]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of ¥2.50 per 10 shares, totaling ¥20,000,000 based on 80,000,000 shares[4]. - The profit distribution plan for 2017 includes a cash dividend of 2.50 CNY per 10 shares, totaling 20,000,000 CNY (after tax), which represents 30.49% of the net profit attributable to ordinary shareholders[102][106]. - The total distributable profit for the year is 166,183,895.86 CNY, with cash dividends accounting for 100% of the profit distribution[102]. Corporate Governance and Compliance - The company has established a governance structure that protects the interests of shareholders, particularly minority shareholders, ensuring compliance with legal regulations[151]. - The company is committed to complying with relevant laws and regulations regarding stock buybacks and shareholder actions[111]. - The company has fulfilled all commitments made by its actual controllers and shareholders during the reporting period[107]. Social Responsibility and Environmental Commitment - The company emphasizes its commitment to social responsibility, focusing on the development of affordable medicines and contributing to societal well-being[150]. - The company has invested in environmental protection, with a wastewater treatment system designed to handle 40 tons per hour, ensuring compliance with discharge standards[156]. - The company has established a robust emergency response plan for environmental incidents, conducting multiple drills to enhance preparedness[158]. Employee Development and Training - The company employed a total of 460 staff members, including 181 production personnel, 93 sales personnel, and 111 technical personnel[196]. - The company organized 228 training sessions during the reporting period, totaling 305 hours of training[199]. - The company plans to enhance its performance evaluation system and link it to employee remuneration to foster a performance-oriented culture[198].

南京海辰药业股份有限公司 2017 年第三季度报告 2017-061 2017 年 10 月 南京海辰药业股份有限公司 2017 年第三季度报告全文 1 南京海辰药业股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)李小卫声明：保证季度报告中财务报表的真实、准确、完整。 2 南京海辰药业股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 574,024,197.32 | | 370,776,229.63 | 54.82% | | 归属于上市公司股东的净资产 | 498,33 ...

Financial Performance - Total revenue for the first half of 2017 reached ¥172,348,187.65, an increase of 42.84% compared to ¥120,660,442.54 in the same period last year[17]. - Net profit attributable to shareholders was ¥29,370,624.56, up 38.52% from ¥21,202,817.91 year-on-year[17]. - Basic earnings per share rose to ¥0.3831, reflecting an 8.40% increase from ¥0.3534 in the same period last year[17]. - The company achieved operating revenue of 172.35 million yuan in the first half of 2017, representing a 42.84% increase year-on-year[36]. - Net profit attributable to shareholders reached 29.37 million yuan, up 38.52% compared to the same period last year[36]. - The company reported a total profit of CNY 34,209,851.25, up from CNY 24,571,070.71, reflecting a year-on-year increase of 39.5%[150]. - The company reported a significant increase in revenue, with a year-on-year growth of 15% in the first half of 2017[188]. Cash Flow and Assets - Net cash flow from operating activities surged to ¥26,192,609.83, a remarkable increase of 462.46% compared to ¥4,656,758.75 in the previous year[17]. - The company’s cash and cash equivalents at the end of the period reached 160,651.60 thousand, reflecting a substantial increase of 555.64% compared to the beginning of the period, primarily due to the proceeds from the initial public offering[29]. - The company reported a net cash inflow from financing activities of ¥160,696,057.15, a dramatic increase of 22,086.91% due to funds raised from the initial public offering[47]. - Total assets at the end of the reporting period were ¥551,423,325.09, representing a 48.72% increase from ¥370,776,229.63 at the end of the previous year[17]. - The company’s cash and cash equivalents increased to ¥160,651,615.88, accounting for 29.13% of total assets, up from 8.18% in the previous year[53]. - Current assets totaled CNY 273,154,766.62, a significant increase from CNY 111,490,217.31, reflecting a growth of about 144.5%[141]. - Total liabilities decreased to CNY 69,513,185.35 from CNY 94,662,719.01, a reduction of approximately 26.6%[142]. Investment and R&D - R&D investment reached CNY 15.04 million, accounting for 8.73% of the company's revenue, representing a year-on-year increase of CNY 5.04 million or 50.45%[40]. - The company is actively pursuing new product development, including injectable Esomeprazole Sodium and Longchun Xiting injection, while also addressing consistency evaluation for previously withdrawn projects[37]. - The company is enhancing its R&D capabilities, with over 60 specialized personnel and a comprehensive R&D system in place[31]. - Research and development expenses rose by 46.16% to ¥14,612,102.99, reflecting the company's commitment to increasing R&D investment[47]. - The company is focusing on high-barrier injectable products, having established a production line for small-volume injectable preparations[31]. - The company plans to expand its solid dosage forms and explore the OTC market for its Lansoprazole enteric-coated tablets[37]. Market Position and Strategy - The company has a diverse product portfolio with 46 varieties and 65 drug production approvals, including key products like Torasemide injection and Cefoperazone sodium injection, which hold significant market shares of 34.64% and 12.7% respectively in major public hospitals[24]. - The company’s market position is strengthened by its inclusion of 37 products in the national medical insurance directory, enhancing accessibility and demand for its offerings[24]. - The company is transitioning its sales model from traditional agency to a more refined promotion model, which is expected to become the main promotional strategy moving forward[27]. - The company focuses on enhancing sales of key products such as Torasemide and Tigecycline, contributing to steady growth in both revenue and net profit during the reporting period[27]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2018[188]. - A strategic acquisition of a smaller competitor is anticipated to enhance the company's product portfolio and increase market competitiveness[188]. Risks and Challenges - The company faces risks including industry policy risks, drug price reduction risks, and new drug development risks[5]. - The company has not made any commitments regarding future plans or performance forecasts, emphasizing the need for investors to recognize associated risks[5]. - The company is subject to risks related to drug bidding price reductions, which could adversely affect its operations if products do not meet expected bidding outcomes[76]. - The company anticipates increased depreciation costs due to the expansion of fixed assets from fundraising projects, which may not yield expected returns if market conditions change[77]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has committed to fulfilling all public commitments made during its initial public offering[97]. - The company has established a stock price stability plan to protect shareholders' interests, particularly for small and medium shareholders, for three years post-IPO[93]. - The controlling shareholders have made commitments to avoid competition and ensure no financial occupation of the company's funds[93]. - The company will ensure that cash dividends in profit distribution will be at least 80% if it is in a mature stage without major capital expenditure plans[92]. Compliance and Reporting - The financial report for the half-year period has not been audited[138]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[180]. - The company believes it has sufficient working capital to continue operations for at least 12 months from the approval date of the financial statements[178].

南京海辰药业股份有限公司 2017 年第一季度报告全文 南京海辰药业股份有限公司 2017 年第一季度报告 2017-32 2017 年 04 月 1 南京海辰药业股份有限公司 2017 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)李小卫声明：保证季度报告中财务报表的真实、准确、完整。 2 南京海辰药业股份有限公司 2017 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 75,587,056.72 | 51,458,943.36 | 46.89% | | 归属于上市公司股东的净利润（元） | 7, ...

南京海辰药业股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 南京海辰药业股份有限公司 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 2016 年年度报告 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)李小卫声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 2017-024 2017 年 04 月 1 南京海辰药业股份有限公司 2016 年年度报告全文 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 5 | | 第三节 公司业务概要 8 | | 第四节 经营情况讨论与分析 11 | | 第五节 重要事项 25 | | 第六节 股份变动及股东情况 45 | | 第七节 优先股相关情况 50 | | 第八节 董事、监事、高级管理人员和员工情况 51 | | 第九节 公司治理 59 | | 第十节 公司债券相关情况 65 | | 第十一节 财务报告 66 | | 第十 ...